[Chimeric antigen receptor T-cell therapy for multiple myeloma].

CAR T-cell therapy is a novel cancer immunotherapy targeting cancer-specific cell-surface antigen. CD19-CAR T cells have been demonstrated to be highly efficacious in treating B-cell leukemia/lymphoma. Currently, several researchers are developing CAR T cells for multiple myeloma. In some early-phase clinical trials, CAR T cells targeting B-cell maturation antigen have exhibited promising efficacy. Recently, we reported that CAR T cells targeting the activated integrin 7 can selectively eradicate MM cells including CD19 clonotypic B cells; a clinical trial for further assessment regarding this study is in process.